×
About 293 results

ALLMedicine™ Thymic Tumors Center

Research & Reviews  107 results

Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathw...
https://doi.org/10.1093/oncolo/oyac115
The Oncologist; Girard N, Basse C et. al.

Jun 25th, 2022 - Thymic malignancies represent a heterogeneous group of rare thoracic cancers, which are classified according to the World Health Organization histopathologic classification, that distinguishes thymomas from thymic carcinomas. Data regarding the bi...

A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
https://clinicaltrials.gov/ct2/show/NCT02220855

Apr 11th, 2022 - Thymic tumors are rare tumors, but represent the most common tumors of the anterior mediastinum. Thymoma has an indolent course in advanced disease and has the propensity to spread to the pleura. In first line therapy, combination chemotherapy pro...

Overview of the 2022 WHO Classification of Thyroid Neoplasms.
https://doi.org/10.1007/s12022-022-09707-3
Endocrine Pathology; Baloch ZW, Asa SL et. al.

Mar 16th, 2022 - This review summarizes the changes in the 5th edition of the WHO Classification of Endocrine and Neuroendocrine Tumors that relate to the thyroid gland. The new classification has divided thyroid tumors into several new categories that allow for a...

Double sternal elevation subxiphoid versus uniportal thoracoscopic thymectomy associate...
https://doi.org/10.1016/j.surg.2021.12.034
Surgery Song N, Li Q et. al.

Feb 16th, 2022 - This study aimed to evaluate the therapeutic efficacy of thymectomy through a subxiphoid video-thoracoscopic approach with double elevation of the sternum compared with traditional intercostal uniportal video-assisted thoracic surgery for stage I-...

The spectrum of sebaceous differentiation in tumors of thymic origin.
https://doi.org/10.1016/j.prp.2021.153702
Pathology, Research and Practice; Weissferdt A

Dec 21st, 2021 - Sebaceous differentiation is an unexpected and unusual phenomenon in the normal thymic gland. Among thymic tumors, sebaceous glands are a relatively common component of mediastinal teratomas but are exceedingly rare in other neoplasms of thymic or...

see more →

Guidelines  2 results

Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagn...
https://doi.org/10.1093/annonc/mds267
Annals of Oncology : Official Journal of the European Soc... Öberg K, Hellman P et. al.

Nov 20th, 2012 - Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2012|Öberg K,Hellman P,Ferolla P,Papotti M, ,|therapeutic use,diagnosis,pathology,therapy,diagnosis,pathology,therapy,diagnosis,p...

Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis,...
https://doi.org/10.1093/annonc/mdn116
Annals of Oncology : Official Journal of the European Soc... Oberg K, Jelic S et. al.

May 9th, 2008 - Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up.|2008|Oberg K,Jelic S, ,|diagnosis,epidemiology,pathology,therapy,diagnosis,epidemiology,pathology,therapy,diagnosis,epidemiology,patho...

see more →

Clinicaltrials.gov  5 results

A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
https://clinicaltrials.gov/ct2/show/NCT02220855

Apr 11th, 2022 - Thymic tumors are rare tumors, but represent the most common tumors of the anterior mediastinum. Thymoma has an indolent course in advanced disease and has the propensity to spread to the pleura. In first line therapy, combination chemotherapy pro...

Prognostic Factors in Patients Submitted to Surgical Treatment for Thymoma
https://clinicaltrials.gov/ct2/show/NCT04577495

Oct 8th, 2020 - Rationale: Even though the World Health Organization (WHO) histological classification and Masaoka-Koga staging system are currently the most widely used, some studies have validated alternative pathologic classifications, as the one proposed by S...

18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma
https://clinicaltrials.gov/ct2/show/NCT01610544

Jul 5th, 2018 - Background: (18)F FLT, a thymidine analog, has uptake in tumors that correlates with proliferative rates and may be an early predictor of tumor response. Due to uptake in inflammatory tissues, routinely used (18)F FDG PET/CT is often unable to dis...

Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
https://clinicaltrials.gov/ct2/show/NCT00314873

Jun 3rd, 2014 - Thymic carcinomas are particularly more concerning due to their aggressive metastatic nature and shorter overall survival, in comparison to their lesser-malignant thymoma counterparts. This necessitates the need for systemic therapy. Due to the pa...

Biology of Thymic Tumors
https://clinicaltrials.gov/ct2/show/NCT00965627

Aug 28th, 2009 - The aim of the present study is to investigated the genetic alterations in tumor samples of a series of all WHO-defined subtypes of thymoma patients using high resolution microarray- comparative genomic hybridization (CGH) followed by hierarchical...

see more →

News  3 results

Dr. Riess Discusses PD-L1 Expression in Thymic Malignancies
https://www.onclive.com/view/dr-riess-discusses-pd-l1-expression-in-thymic-malignancies

Dec 20th, 2020 - Jonathan Riess, MD, MS, Assistant Professor of Medicine, Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses PD-L1 expression in a thymoma tissue microarray. As PD-1 and PD-L1 antibodies have demonstrated benefit in other tum...

Looking Forward: Experts Discuss Exciting Trends in 2012 Oncology Drug Pipeline
https://www.onclive.com/view/looking-forward-experts-discuss-exciting-trends-in-2012-oncology-drug-pipeline

Dec 5th, 2020 - Pharmaceutical companies are investing billions of dollars in a new age of oncology. The more than 900 cancer medications in the pipelines at drug companies and academic institutions constitute nearly 40% of all the drugs under development, accord...

Group finds a way to target MDSCs
https://www.mdedge.com/hematology-oncology/article/185891/lymphoma-plasma-cell-disorders/group-finds-way-target-mdscs
HT Staff

Jun 1st, 2014 - Lab mouse Researchers say they’ve found a way to target myeloid-derived suppressor cells (MDSCs) while sparing other immune cells. In preclinical experiments, the team showed they could deplete MDSCs—and shrink tumors—using peptide antibodies.

see more →